Читаем Остеопороз полностью

Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci. 2002. 47(8): 1665–78.

Halkin H., Dushenat M., Silverman B. еt al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother. 2007. 41(1): 29–34.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021817s003lbl.pdf

http://www.biomedcentral.com/content/pdf/1471-2474-10-113.pdf

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150837.htm

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079352.htm

Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the longterm use of bisphosphonates: a case series from a Swiss university hospital // Drug Saf. 2009. Vol. 32. Р. 775–785.

Jackson R.D., LaCroix A.Z., Gass M. et al. (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683; Hsia J., Heiss G., Ren H. et al. (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115: 846–854.

Janja Zupan, Radko Komadina, Janja Marc. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues // J Biomed Sci. 2012; 19(1): 28. Published online 2012 March 1.

Jarvinen T.L.N., Sievanen H., Khan K.M., Heinonen А., Kannus Р. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008. 336: 124–126.

Kendler D., Kung A.W., Fuleihan Gel H. et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate // Maturitas. 2004. V. 48. P. 243–251.

Lampropoulos, C. E. et al. Osteoporosis – a risk factor for cardiovascular disease? // Nat. Rev. Rheumatol. advance online publication 14 August 2012.

Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., Locklin R.M., Ebetino F.H., Russell R.G. Differences between bisphosphonates in binding affinities for hydroxyapatite // J. Biomed Mater Res B Appl Biomater. 2009. Vol. 92B. Р. 149–155.

Leung S., Ashar B.H., Miller R.G. Bisphosphonate-associated scleritis: a case report and review // South Med. 2005. Vol. 98. Р. 733–735.

Lewis J.R., Calver J., Zhu K., Flicker L., Prince R.L. (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCTand a 4,5-year follow-up. J Bone Miner Res 26: 35–41.

Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A. et. al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture // New England J. Medicine. 2007. Vol. 357. Р. 1799–1809.

MacLean C., NewbeОРy S., Maglione M., McMahon M., Ranganath V., Suttorp M., Mojica W., Timmer M., Alexander A., McNamara M., Desai S.B., Zhou A., Chen S., Carter J., Tringale C., Valentine D., Johnsen B., Grossman J. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008. Feb 5.148(3): 197–213.

Mak A. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskeletal Disorders. 2009, 10: 113.

Martin Fortin, Moira Stewart, Marie-Eve Poitras, José Almirall, Heather Maddocks. Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology // Ann Fam Med March/April 2012 vol. 10 no. 2 142–151.

Mavrokokki T., Cheng A., Stein B., Goss A. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia // J. Oral Maxillofac Surg. 2007. Vol. 65. Р. 415–423.